Mutations in the rod-expressed gene, cyclic nucleotide-gated channel beta subunit (CNGB1) and associated inborn errors in metabolism are causes of retinal disease that causes progressive loss of vision. Retinitis pigmentosa (RP) is a major cause of untreatable blindness associated with CNGB1 (CNGB1-RP). RP involves the death of photoreceptor cells that can be caused by mutations in a number of different genes. Treatment by gene therapy could prevent blindness in cases of inherited retinal dystrophies including RP. In the future RP due to mutations in CNGB1 may be treatable by gene therapy since this form of photoreceptor degeneration involves a slow loss of rod photoreceptor cells. This provides a wide window of opportunity for the identification of patients and initiation of treatment. Our efforts are directed toward developing gene therapy as a treatment. To this end, our objective is to better understand the disease process of CNGB1-RP and other allied inherited disorders so that we can develop clinical tests to measure the outcomes of treatment.
Study Type
OBSERVATIONAL
Enrollment
20
The objective is to better understand the disease process of CNGB1-RP so that we can develop clinical tests to measure the outcomes of treatment.
Dr. Stephen H. Tsang
New York, New York, United States
RECRUITINGWills Eye Hospital
Philadelphia, Pennsylvania, United States
RECRUITINGInstitut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts
Paris, France
RECRUITINGKlinikum der Universität München University Eye Hospital, Ludwig-Maximilians-University (LMU) Munich
München, Bavaria, Germany
RECRUITINGEberhard Karls University Tubingen
Tübingen, Germany
RECRUITINGMoorfields Eye Hospital NHS Foundation Trust
London, United Kingdom
NOT_YET_RECRUITINGWe will be looking to identify what the best outcome measurements will be for CNGB1-RP in order to use these measurements in a future clinical trial.
Both structural imaging and functional tests will be used to characterize the natural history progression of CNGB1-RP.
Time frame: 2 days, 1 time per year, for 3 years
Medmont Dark Adapted Chromatic (DAC) Automated Perimeter
Time frame: 1 time per year, for 3 years
Full-field ERG (ISCEV Protocol)
Time frame: 1 time per year, for 3 years
Optical Coherence Tomography (OCT)
Time frame: 1 time per year, for 3 years
Fundus Autofluorescence (FAF)
Time frame: 1 time per year, for 3 years
Near-infrared fundus autofluorescence (NIR-AF)
Time frame: 1 time per year, for 3 years
Quantitative Fundus Autofluorescence (qAF)
Time frame: 1 time per year, for 3 years
Best-corrected Visual Acuity (BCVA)
Time frame: 1 time per year, for 3 years
Complete Ophthalmic Exam
Time frame: 2 time per year, for 3 years
Color Fundus Photos
Time frame: 1 time per year, for 3 years
MAIA Microperimetry
if available
Time frame: 1 time per year, for 3 years
NIDEK Microperimetry
if available
Time frame: 1 time per year, for 3 years
Goldman Kinetic Visual Field
Time frame: 1 time per year, for 3 years
Light-adapted Static Perimetry
Time frame: 1 time per year, for 3 years
Panel D-15 Colour Vision (desat.)
Time frame: 1 time per year, for 3 years
Dark-adapted Chromatic Perimetry
Time frame: 1 time per year, for 3 years
Full-field Stimulus Testing (FST)
Optional
Time frame: 1 time per year, for 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.